Foresee Pharmaceuticals Co., Ltd.

Feb 21, 2019

Foresee Pharmaceuticals Announces Successful Topline Results from Phase 3 Registration Study of LMIS 25 mg in Prostate Cancer

Feb 11, 2019

Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare

Nov 26, 2018

Foresee Pharmaceuticals Announces Completion of Last Patient Visit in Registration Phase 3 Study of LMIS 25 mg (fp-001) for the Treatment of Advanced Prostate Cancer

Nov 15, 2018

Foresee Pharmaceuticals Announces Sr. VP of Pharmaceutics and Manufacturing Appointment

Jul 26, 2018

Foresee Pharmaceuticals Announces Results from a Phase 1 Clinical Study, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of FP-045, a Potent ALDH2 Activator

Jan 03, 2018

Foresee Pharmaceuticals and Megapharm Announce License and Distribution Agreement

Dec 04, 2017

Foresee Pharmaceuticals Announces Results from Phase 1 Clinical Studies

Sep 27, 2017

Foresee Pharmaceuticals and TRPharm Announce License and Distribution Agreement